News Focus
News Focus
icon url

learningcurve2020

01/24/26 10:22 AM

#811169 RE: seekinganswers #811168

The trial was nebulous and without a confirmatory useless for shareholders, imo. But good research came from it on retails dime.
icon url

SkyLimit2022

01/24/26 11:45 AM

#811188 RE: seekinganswers #811168

seekazy,



Thanks for posting your free expert opinion on the PIII clinical trial, but we’ll leave the analyses & conclusions to the independent peer reviewers, the
FDA, & the respected physicians who led the trial.

Dr. Ashkan

Dr. Liau

To clarify the mis- or disinformation, & for details about the DCVax®-L PIII clinical trial, the most comprehensive resource is the independent peer review that was published in JAMA Oncology.



☑️ There are multiple trials & trial designs relevant to NWBO that include either a DCVax product or Roswell’s aDC1 platform.

☑️ Beyond the PIII ECA, DCVax®-L is also being studied in a RCT setting with placebo group.

☑️ As a matter of record, OS was always one of the endpoints for the PIII, but OS replaced PFS as the
primary endpoint.

Bullish
Bullish